This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics
May 14-17, 2024 | In-Person + Digital
Boston, MA, USAHynes Convention Center

Dr. Michael Cochran, PhD
Director of Chemistry at Avidity Biosciences


Scientist with over ten years of experience in industry developing antibody-oligonucleotide conjugates, nanoparticles, and antigen-adjuvant conjugates to improve treatments for rare muscular diseases, oncology, and vaccines. At Avidity, Michael has worked on the chemistry of antibody-siRNA and PMO conjugates from preclinical discovery through GMP manufacturing.

Agenda Sessions

  • Recent Progress with Antibody PMO Conjugates